S&P 500   2,553.62 (+0.48%)
DOW   21,610.12 (-0.12%)
QQQ   186.95 (+0.89%)
AAPL   249.90 (+0.87%)
FB   158.64 (+1.18%)
MSFT   154.72 (+3.35%)
GOOGL   1,102.14 (-0.73%)
AMZN   1,918.12 (+0.95%)
CGC   13.89 (-6.46%)
NVDA   254.39 (+0.66%)
BABA   187.60 (-0.52%)
MU   43.23 (-0.57%)
GE   7.40 (-2.89%)
TSLA   495.56 (-3.66%)
AMD   46.87 (+0.62%)
T   29.74 (-0.37%)
ACB   0.92 (-10.68%)
F   4.96 (-4.43%)
NFLX   361.82 (+1.32%)
BAC   21.45 (-0.69%)
GILD   75.58 (+3.75%)
PRI   86.99 (-3.30%)
DIS   92.88 (-3.65%)
S&P 500   2,553.62 (+0.48%)
DOW   21,610.12 (-0.12%)
QQQ   186.95 (+0.89%)
AAPL   249.90 (+0.87%)
FB   158.64 (+1.18%)
MSFT   154.72 (+3.35%)
GOOGL   1,102.14 (-0.73%)
AMZN   1,918.12 (+0.95%)
CGC   13.89 (-6.46%)
NVDA   254.39 (+0.66%)
BABA   187.60 (-0.52%)
MU   43.23 (-0.57%)
GE   7.40 (-2.89%)
TSLA   495.56 (-3.66%)
AMD   46.87 (+0.62%)
T   29.74 (-0.37%)
ACB   0.92 (-10.68%)
F   4.96 (-4.43%)
NFLX   361.82 (+1.32%)
BAC   21.45 (-0.69%)
GILD   75.58 (+3.75%)
PRI   86.99 (-3.30%)
DIS   92.88 (-3.65%)
S&P 500   2,553.62 (+0.48%)
DOW   21,610.12 (-0.12%)
QQQ   186.95 (+0.89%)
AAPL   249.90 (+0.87%)
FB   158.64 (+1.18%)
MSFT   154.72 (+3.35%)
GOOGL   1,102.14 (-0.73%)
AMZN   1,918.12 (+0.95%)
CGC   13.89 (-6.46%)
NVDA   254.39 (+0.66%)
BABA   187.60 (-0.52%)
MU   43.23 (-0.57%)
GE   7.40 (-2.89%)
TSLA   495.56 (-3.66%)
AMD   46.87 (+0.62%)
T   29.74 (-0.37%)
ACB   0.92 (-10.68%)
F   4.96 (-4.43%)
NFLX   361.82 (+1.32%)
BAC   21.45 (-0.69%)
GILD   75.58 (+3.75%)
PRI   86.99 (-3.30%)
DIS   92.88 (-3.65%)
S&P 500   2,553.62 (+0.48%)
DOW   21,610.12 (-0.12%)
QQQ   186.95 (+0.89%)
AAPL   249.90 (+0.87%)
FB   158.64 (+1.18%)
MSFT   154.72 (+3.35%)
GOOGL   1,102.14 (-0.73%)
AMZN   1,918.12 (+0.95%)
CGC   13.89 (-6.46%)
NVDA   254.39 (+0.66%)
BABA   187.60 (-0.52%)
MU   43.23 (-0.57%)
GE   7.40 (-2.89%)
TSLA   495.56 (-3.66%)
AMD   46.87 (+0.62%)
T   29.74 (-0.37%)
ACB   0.92 (-10.68%)
F   4.96 (-4.43%)
NFLX   361.82 (+1.32%)
BAC   21.45 (-0.69%)
GILD   75.58 (+3.75%)
PRI   86.99 (-3.30%)
DIS   92.88 (-3.65%)
Log in

NASDAQ:CYTK - Cytokinetics Stock Price, Forecast & News

$11.39
-0.36 (-3.06 %)
(As of 03/30/2020 09:47 AM ET)
Today's Range
$11.37
Now: $11.39
$11.94
50-Day Range
$8.75
MA: $13.26
$16.30
52-Week Range
$7.72
Now: $11.39
$16.96
Volume14,524 shs
Average Volume918,820 shs
Market Capitalization$677.14 million
P/E RatioN/A
Dividend YieldN/A
Beta1.16
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, as well as in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274, a novel cardiac myosin inhibitor, which is in Phase I clinical trial for the potential treatment of hypertrophic cardiomyopathy; and AMG 594, a novel cardiac troponin activator that is in Phase I clinical trial. The company has strategic alliances with Amgen Inc. and Astellas Pharma Inc. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.
Read More
Cytokinetics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CYTK
CUSIPN/A
Phone650-624-3000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$26.87 million
Book Value($0.19) per share

Profitability

Net Income$-121,690,000.00
Net Margins-452.92%
Return on Equity-10,351.99%

Miscellaneous

Employees130
Market Cap$677.14 million
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive CYTK News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.


Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions

How has Cytokinetics' stock been impacted by COVID-19 (Coronavirus)?

Cytokinetics' stock was trading at $12.03 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CYTK stock has decreased by 2.5% and is now trading at $11.73. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cytokinetics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cytokinetics.

When is Cytokinetics' next earnings date?

Cytokinetics is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Cytokinetics.

How were Cytokinetics' earnings last quarter?

Cytokinetics, Inc. (NASDAQ:CYTK) posted its quarterly earnings data on Tuesday, March, 3rd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.08. The biopharmaceutical company had revenue of $5.21 million for the quarter, compared to analysts' expectations of $7.19 million. Cytokinetics had a negative return on equity of 10,351.99% and a negative net margin of 452.92%. View Cytokinetics' earnings history.

What guidance has Cytokinetics issued on next quarter's earnings?

Cytokinetics issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, March, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $18-22 million, compared to the consensus revenue estimate of $28.03 million.

What price target have analysts set for CYTK?

6 equities research analysts have issued 12 month price objectives for Cytokinetics' shares. Their forecasts range from $16.00 to $30.00. On average, they expect Cytokinetics' stock price to reach $22.17 in the next year. This suggests a possible upside of 89.0% from the stock's current price. View analysts' price targets for Cytokinetics.

Has Cytokinetics been receiving favorable news coverage?

Media headlines about CYTK stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Cytokinetics earned a news impact score of -1.0 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutCytokinetics.

Are investors shorting Cytokinetics?

Cytokinetics saw a decrease in short interest in the month of March. As of March 13th, there was short interest totaling 7,830,200 shares, a decrease of 6.1% from the February 27th total of 8,340,000 shares. Based on an average trading volume of 749,000 shares, the short-interest ratio is currently 10.5 days. Currently, 14.4% of the shares of the company are short sold. View Cytokinetics' Current Options Chain.

Who are some of Cytokinetics' key competitors?

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Amgen (AMGN), Novavax (NVAX), TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Geron (GERN), TG Therapeutics (TGTX) and Progenics Pharmaceuticals (PGNX).

Who are Cytokinetics' key executives?

Cytokinetics' management team includes the following people:
  • Mr. Robert I. Blum, CEO, Pres & Director (Age 55)
  • Mr. Ching W. Jaw, Sr. VP & CFO (Age 56)
  • Dr. Andrew A. Wolff, Sr. VP & Chief Medical Officer (Age 64)
  • Dr. Fady Ibraham Malik, Exec. VP of R&D (Age 55)
  • Dr. Bradley Paul Morgan, Sr. VP of Research & Non-Clinical Devel. (Age 59)

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Who are Cytokinetics' major shareholders?

Cytokinetics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BVF Inc. IL (12.20%), Driehaus Capital Management LLC (5.14%), Point72 Asset Management L.P. (5.13%), State Street Corp (4.30%), FMR LLC (3.02%) and Geode Capital Management LLC (1.35%). Company insiders that own Cytokinetics stock include Bvf Partners L P/Il, Fady Ibraham Malik, Robert I Blum and Value Fund L P Biotechnology. View institutional ownership trends for Cytokinetics.

Which institutional investors are selling Cytokinetics stock?

CYTK stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Citigroup Inc., UBS Group AG, Pinnacle Associates Ltd., South Dakota Investment Council, Arizona State Retirement System, Chicago Equity Partners LLC, and Credit Suisse AG. Company insiders that have sold Cytokinetics company stock in the last year include Bvf Partners L P/Il, Fady Ibraham Malik, and Robert I Blum. View insider buying and selling activity for Cytokinetics.

Which institutional investors are buying Cytokinetics stock?

CYTK stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, Point72 Asset Management L.P., Jennison Associates LLC, Jacobs Levy Equity Management Inc., Driehaus Capital Management LLC, State Street Corp, Goldman Sachs Group Inc., and Mirador Capital Partners LP. Company insiders that have bought Cytokinetics stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology. View insider buying and selling activity for Cytokinetics.

How do I buy shares of Cytokinetics?

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cytokinetics' stock price today?

One share of CYTK stock can currently be purchased for approximately $11.73.

How big of a company is Cytokinetics?

Cytokinetics has a market capitalization of $697.35 million and generates $26.87 million in revenue each year. The biopharmaceutical company earns $-121,690,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Cytokinetics employs 130 workers across the globe. View additional information about Cytokinetics.

What is Cytokinetics' official website?

The official website for Cytokinetics is http://www.cytokinetics.com/.

How can I contact Cytokinetics?

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]


MarketBeat Community Rating for Cytokinetics (NASDAQ CYTK)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  657 (Vote Outperform)
Underperform Votes:  283 (Vote Underperform)
Total Votes:  940
MarketBeat's community ratings are surveys of what our community members think about Cytokinetics and other stocks. Vote "Outperform" if you believe CYTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel